COMP <GO>
GNTA vs MGX // EV/EBITDA & P/E VALUATION
Genenta Science S.p.A. (NASDAQ) VS. Metagenomi Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: GNTA 1
— MGX 1
■ METRIC PARITY
LAST: $0.62 (+2.48%) • MKT CAP: $29.9M
valuation
—
LAST: $0.83 (+1.03%) • MKT CAP: $31.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GNTA VS. MGX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GNTA | MGX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -51.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 1/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.5 | 30.9 | +5.60 | GNTA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.9M | $31.4M | -$1.5M | MGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GNTA REV | MGX REV | GNTA GROSS % | MGX GROSS % | GNTA FCF | MGX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $25.2M | — | — | — | -$89.5M |
| FY 2024 | — | $52.3M | — | — | — | -$112.2M |
| FY 2023 | — | $44.8M | — | — | — | -$91.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GNTA // BETA —
MGX // BETA —